PIK3CA hypomethylation plays a key role in activation of the PI3K/AKT pathway in esophageal cancer in Chinese patients

被引：0
|
作者：
Wei-feng Wang
Yan Xie
Zhi-hua Zhou
Zheng-hong Qin
Jun-chao Wu
Jing-kang He
机构：
[1] First Affiliated Hospital of Soochow University,Department of Chest Surgery
[2] The 101st Hospital of the People's Liberation Army,Department of Pathology
[3] Laboratory of Aging and Nervous Diseases,undefined
[4] Soochow University,undefined
来源：
Acta Pharmacologica Sinica | 2013年 / 34卷
关键词：
esophageal cancer; oncogene; PIK3CA; PI3K/AKT pathway; gene mutation; methylation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1560 / 1567
页数：7
相关论文
共 50 条
  • [31] Targeting the PI3K/AKT/mTOR pathway for the treatment of metaplastic breast cancer: Does location of PIK3CA mutation or histology affect response
    Basho, Reva K.
    Gilcrease, Michael
    Murthy, Rashmi K.
    Helgason, Thorunn
    Booser, Daniel J.
    Karp, Daniel D.
    Meric-Bernstam, Funda
    Hess, Kenneth R.
    Herbrich, Shelley M.
    Valero, Vicente
    Albarracin, Constance
    Litton, Jennifer
    -MacGregor, Mariana Chavez
    Ibrahim, Nuhad K.
    Murray, James L.
    Koenig, Kimberly B.
    Hong, David
    Subbiah, Vivek
    Kurzrock, Razelle
    Janku, Filip
    Moulder, Stacy
    CANCER RESEARCH, 2016, 76
  • [32] PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation
    Liu, Songlin
    Tang, Yunhong
    Yan, Maomao
    Jiang, Weixi
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (05) : 763 - 772
  • [33] PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation
    Songlin Liu
    Yunhong Tang
    Maomao Yan
    Weixi Jiang
    Investigational New Drugs, 2018, 36 : 763 - 772
  • [34] Understanding PI3K/Akt/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example
    Zheng, Shutao
    He, Shuo
    Liang, Yan
    Tan, Yiyi
    Liu, Qing
    Liu, Tao
    Lu, Xiaomei
    MOLECULAR BIOMEDICINE, 2024, 5 (01):
  • [35] Dissecting PI3K-AKT pathway by phosphoproteomic profiling of PIK3CA knock-in mutants
    Wu, Xinyan
    Sahasrabuddhe, Nandini A.
    Renuse, Santosh
    Zahari, Saddiq
    Chaerkady, Raghothama
    Mohseni, Morassa
    Yang, Jian
    Kim, Min-Sik
    Zhong, Jun
    Qian, Jiang
    Zhu, Heng
    Vogelstein, Bert
    Park, Ben Ho
    Pandey, Akhilesh
    CANCER RESEARCH, 2012, 72
  • [36] Assessing PIK3CA and PTEN in Early-Phase Trials with PI3K/AKT/mTOR Inhibitors
    Janku, Filip
    Hong, David S.
    Fu, Siqing
    Piha-Paul, Sarina A.
    Naing, Aung
    Falchook, Gerald S.
    Tsimberidou, Apostolia M.
    Stepanek, Vanda M.
    Moulder, Stacy L.
    Lee, J. Jack
    Luthra, Rajyalakshmi
    Zinner, Ralph G.
    Broaddus, Russell R.
    Wheler, Jennifer J.
    Kurzrock, Razelle
    CELL REPORTS, 2014, 6 (02): : 377 - 387
  • [37] Activation of the PI3K/Akt pathway in neuroblastoma
    Sartelet, Herve
    Castaing, Marine
    Fabre, Monique
    Bosq, Jacques
    Rougemont, Anne-Laure
    Michieis, Stefan
    Vassal, Gilles
    VIRCHOWS ARCHIV, 2007, 451 (02) : 130 - 130
  • [38] Activation of the PI3K/Akt pathway in neuroblastoma
    Sartelet, H.
    Castain, M.
    Fabre, M.
    Bosq, J.
    Rougemont, A.
    Michiels, S.
    Vassal, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] Diagnostic application of PIK3CA mutation analysis in Chinese esophageal cancer patients
    Ming, Zizhen
    Jiang, Dongxian
    Hu, Qin
    Li, Xiaojing
    Huang, Jie
    Xu, Yifan
    Liu, Yalan
    Xu, Chen
    Hua, Xiuguo
    Hou, Yingyong
    DIAGNOSTIC PATHOLOGY, 2014, 9
  • [40] Diagnostic application of PIK3CA mutation analysis in Chinese esophageal cancer patients
    Zizhen Ming
    Dongxian Jiang
    Qin Hu
    Xiaojing Li
    Jie Huang
    Yifan Xu
    Yalan Liu
    Chen Xu
    Xiuguo Hua
    Yingyong Hou
    Diagnostic Pathology, 9
12345